Download PDF

1. Company Snapshot

1.a. Company Description

Redcare Pharmacy NV owns and operates online pharmacies in Germany, Austria, Switzerland, France, Belgium, Italy, and the Netherlands.It provides prescription medications, over-the-counter medications, and pharmacy-related beauty and personal care products, as well as food supplements.The company was formerly known as Shop Apotheke Europe N.V. and changed its name to Redcare Pharmacy NV in June 2023.


The company was founded in 2001 and is headquartered in Sevenum, the Netherlands.

Show Full description

1.b. Last Insights on RDC

Redcare Pharmacy NV's recent performance was negatively impacted by a mediocre Q3 earnings release, which led to a downgrade in analyst estimates. Despite sustained positive sales performance in both Rx and Non-Rx segments, with total sales up 25% to EUR 719M in Q3, concerns arose. The appointment of Hendrik Krampe as CFO, effective December 1, 2025, may bring new financial leadership. However, the preceding departure of Jasper Eenhorst and a 12% drop in share value following the earnings release likely contributed to the negative performance.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

3. NewsRoom

Card image cap

European Growth Companies With High Insider Ownership For November 2025

Nov -20

Card image cap

Redcare Pharmacy appoints Hendrik Krampe as CFO

Nov -11

Card image cap

Change in Redcare Pharmacy's Managing Board: New CFO Hendrik Krampe

Nov -10

Card image cap

Redcare Pharmacy NV (ETR:RDC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Nov -01

Card image cap

European Growth Companies Insiders Are Investing In

Oct -22

Card image cap

Redcare Pharmacy Confirms Full-year Guidance Following Sustained Positive Q3 Sales Performance in Both Rx and Non-Rx

Oct -06

Card image cap

European Growth Companies With Insider Ownership Up To 36%

Sep -23

Card image cap

European Growth Stocks With Strong Insider Ownership

Aug -25

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (7.41%)

6. Segments

DACH

Expected Growth: 7.18%

DACH region's growing elderly population, increasing healthcare expenditure, and rising demand for chronic disease management drive Redcare Pharmacy NV's 7.18% growth. Additionally, the region's strong economy, favorable reimbursement policies, and increasing adoption of digital healthcare solutions contribute to the company's expansion.

International

Expected Growth: 8.37%

Redcare Pharmacy NV's 8.37% international growth is driven by increasing demand for specialty medicines, expansion into emerging markets, and strategic partnerships with local healthcare providers. Additionally, the company's investment in digital healthcare platforms and e-commerce capabilities has enhanced customer reach and accessibility, contributing to its growth momentum.

7. Detailed Products

Prescription Medication

Redcare Pharmacy NV offers a wide range of prescription medications for various health conditions, including chronic diseases and acute illnesses.

Over-the-Counter (OTC) Medication

The pharmacy offers a variety of OTC medications for common health issues, such as pain relief, allergies, and digestive problems.

Vitamins and Supplements

Redcare Pharmacy NV provides a range of vitamins and supplements to support overall health and wellness.

Health and Beauty Products

The pharmacy offers a selection of health and beauty products, including skincare, haircare, and personal care items.

Medical Equipment and Supplies

Redcare Pharmacy NV provides medical equipment and supplies, such as wheelchairs, walkers, and diabetic testing strips.

Consultation Services

The pharmacy offers consultation services with licensed pharmacists and healthcare professionals.

8. Redcare Pharmacy NV's Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Redcare Pharmacy NV is moderate due to the presence of alternative pharmacies and online retailers.

Bargaining Power Of Customers

The bargaining power of customers is low due to the lack of price sensitivity and the importance of convenience in the pharmacy industry.

Bargaining Power Of Suppliers

The bargaining power of suppliers is moderate due to the presence of multiple suppliers and the importance of maintaining relationships with them.

Threat Of New Entrants

The threat of new entrants is high due to the relatively low barriers to entry and the attractiveness of the pharmacy industry.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of multiple competitors and the importance of differentiating oneself in the market.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 33.29%
Debt Cost 6.91%
Equity Weight 66.71%
Equity Cost 9.26%
WACC 8.48%
Leverage 49.91%

11. Quality Control: Redcare Pharmacy NV passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Fielmann

A-Score: 6.0/10

Value: 5.3

Growth: 5.0

Quality: 7.3

Yield: 4.4

Momentum: 6.5

Volatility: 7.7

1-Year Total Return ->

Stock-Card
Sobi

A-Score: 4.8/10

Value: 3.1

Growth: 7.3

Quality: 7.4

Yield: 0.0

Momentum: 5.0

Volatility: 5.7

1-Year Total Return ->

Stock-Card
Camurus

A-Score: 4.4/10

Value: 0.0

Growth: 9.3

Quality: 9.0

Yield: 0.0

Momentum: 6.0

Volatility: 2.0

1-Year Total Return ->

Stock-Card
Synlab

A-Score: 4.1/10

Value: 5.7

Growth: 8.0

Quality: 3.7

Yield: 1.9

Momentum: 4.0

Volatility: 1.7

1-Year Total Return ->

Stock-Card
Virbac

A-Score: 4.0/10

Value: 3.1

Growth: 6.3

Quality: 6.5

Yield: 0.0

Momentum: 2.0

Volatility: 6.3

1-Year Total Return ->

Stock-Card
Redcare Pharmacy

A-Score: 2.9/10

Value: 6.0

Growth: 6.9

Quality: 3.2

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

62.1$

Current Price

62.1$

Potential

-0.00%

Expected Cash-Flows